A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation - PubMed (original) (raw)
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation
Babak Baban et al. Int Immunol. 2005 Jul.
Abstract
By ligating CD80/CD86 (B7) molecules, the synthetic immunomodulatory reagent CTLA4-Ig (soluble synthetic CTLA4 fusion protein) induces expression of the enzyme indoleamine 2,3-dioxygenase (IDO) in some dendritic cells (DCs), which acquire potent T cell regulatory functions as a consequence. Here we show that this response occurred exclusively in a population of splenic DCs co-expressing the marker CD19. B7 ligation induced activation of the transcription factor signal transducer and activator of transcription (STAT1) in sorted CD19+, but not CD19(NEG), DCs. STAT1 activation occurred even when DCs lacked receptors for type II IFN (IFNgamma); however, STAT1 activation and IDO up-regulation were not observed when DCs lacked receptors for type I IFN (IFNalphabeta). Thus, IFNalpha, but not IFNgamma, signaling was essential for STAT1 activation and IDO up-regulation in CD19+ DCs following B7 ligation. Consistent with these findings, B7 ligation also induced sorted CD19+, but not CD19(NEG), DCs to express IFNalpha. Moreover, recombinant IFNalpha induced CD19+, but not CD19(NEG), DCs to mediate IDO-dependent T cell suppression, showing that IFNalpha signaling could substitute for upstream signals from B7. These data reveal that a minor population of splenic DCs expressing the CD19 marker is uniquely responsive to B7 ligation, and that IFNalpha-mediated STAT1 activation is an essential intermediary signaling pathway that promotes IDO induction in these DCs. Thus, CD19+ DCs may be a target for regulatory T cells expressing surface CTLA4, and may suppress T cell responses via induction of IDO.
Similar articles
- Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells.
Manlapat AK, Kahler DJ, Chandler PR, Munn DH, Mellor AL. Manlapat AK, et al. Eur J Immunol. 2007 Apr;37(4):1064-71. doi: 10.1002/eji.200636690. Eur J Immunol. 2007. PMID: 17343295 - Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.
Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH. Mellor AL, et al. Int Immunol. 2004 Oct;16(10):1391-401. doi: 10.1093/intimm/dxh140. Epub 2004 Sep 6. Int Immunol. 2004. PMID: 15351783 - Inhibition of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-dioxygenase.
Funeshima N, Fujino M, Kitazawa Y, Hara Y, Hara Y, Hayakawa K, Okuyama T, Kimura H, Li XK. Funeshima N, et al. J Gene Med. 2005 May;7(5):565-75. doi: 10.1002/jgm.698. J Gene Med. 2005. PMID: 15543532 - Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.
Chen L. Chen L. Nat Rev Immunol. 2004 May;4(5):336-47. doi: 10.1038/nri1349. Nat Rev Immunol. 2004. PMID: 15122199 Review. No abstract available. - T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.
Kahler DJ, Mellor AL. Kahler DJ, et al. Handb Exp Pharmacol. 2009;(188):165-96. doi: 10.1007/978-3-540-71029-5_8. Handb Exp Pharmacol. 2009. PMID: 19031026 Free PMC article. Review.
Cited by
- Time Dimension Influences Severity of Stroke and Heightened Immune Response in Mice.
Kamat PK, Khan MB, Siddiqui S, Williams D, da Silva Lopes Salles E, Naeini SE, Arbab AS, Rudic DR, Baban B, Dhandapani KM, Hess DC. Kamat PK, et al. Transl Stroke Res. 2023 Dec 13. doi: 10.1007/s12975-023-01226-5. Online ahead of print. Transl Stroke Res. 2023. PMID: 38091188 - The impact of exosomes derived from distinct sources on rheumatoid arthritis.
Zhang S, Duan Z, Liu F, Wu Q, Sun X, Ma H. Zhang S, et al. Front Immunol. 2023 Jul 27;14:1240747. doi: 10.3389/fimmu.2023.1240747. eCollection 2023. Front Immunol. 2023. PMID: 37575235 Free PMC article. Review. - BIN1 in cancer: biomarker and therapeutic target.
Chen SY, Cao JL, Li KP, Wan S, Yang L. Chen SY, et al. J Cancer Res Clin Oncol. 2023 Aug;149(10):7933-7944. doi: 10.1007/s00432-023-04673-7. Epub 2023 Mar 9. J Cancer Res Clin Oncol. 2023. PMID: 36890396 Review. - High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies.
Wilfong EM, Bartkowiak T, Vowell KN, Westlake CS, Irish JM, Kendall PL, Crofford LJ, Bonami RH. Wilfong EM, et al. Front Immunol. 2022 Feb 21;13:756018. doi: 10.3389/fimmu.2022.756018. eCollection 2022. Front Immunol. 2022. PMID: 35371068 Free PMC article. - Tryptophan Metabolism via Kynurenine Pathway: Role in Solid Organ Transplantation.
Zulpaite R, Miknevicius P, Leber B, Strupas K, Stiegler P, Schemmer P. Zulpaite R, et al. Int J Mol Sci. 2021 Feb 15;22(4):1921. doi: 10.3390/ijms22041921. Int J Mol Sci. 2021. PMID: 33671985 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous